Cam Skaugrud retweeted
21 year old college baseball player Davis Heller died on his sofa studying for a test, nine months after receiving a Covid shot. He had a medical exemption but @UofAlabama would not accept it.
Davis was an accomplished athlete with an incredibly positive attitude who said he wanted to be the “best teammate in the country.” He struggled with the decision to get the COVID shot but succumbed so he could fulfill his dream to play collegiate baseball.
Cam Skaugrud retweeted
We’re pleased to share that a Genelux Trial-in-Progress abstract has been accepted for presentation at #SITC26!
The presentation will highlight the clinical trial design and science supporting the VIRO-25 clinical trial evaluating Olvimulogene Nanivacirepvec (Olvi-Vec), an oncolytic vaccinia virus-based immunotherapy, in combination with chemotherapy and an immune checkpoint inhibitor in non-small cell lung cancer.
Abstract #540: Clinical trial of Olvimulogene Nanivacirepvec (Olvi-Vec), an oncolytic vaccinia virus-based immunotherapy, plus chemotherapy and an immune checkpoint inhibitor in Non-Small Cell Lung Cancer (VIRO-25).
We look forward to seeing you in Phoenix, Nov. 4–8!
Learn more about the @sitcancer's 41st Annual Meeting and register: sitcancer.org/2026/home
Cam Skaugrud retweeted
Meet the People Behind the Mission: Jane LeBlanc
For Jane LeBlanc, helping patients has been the driving force behind her entire career. Before joining Genelux, she spent more than two decades in oncology clinical research and witnessed firsthand the impact emerging therapies can have on patients facing difficult diagnoses.
Today, as Director, Clinical Site Liaison, Jane works closely with clinical trial sites to support engagement, patient enrollment, and high-quality trial execution, helping bring potential new treatment options to those who need them most.
We're proud to spotlight team members like Jane, whose dedication helps bring hope to patients and advance our mission every day.
#Genelux #EmployeeSpotlight #ClinicalResearch #Oncology #PeopleBehindTheMission #RedefiningImmunoOncology
Cam Skaugrud retweeted
Olvi-Vec is administered regionally in our OnPrime Phase 3 trial for platinum-resistant/recurrent ovarian cancer and is also designed to support future intravenous administration.
Olvi-Vec holds promise for addressing multiple cancer types.
-Systemic administration of Olvi-Vec is being evaluated in clinical trials to directly kill metastatic disease.
-Re-dosing could enable sustained immune engagement.
-Olvi-Vec has shown potential to treat multiple tumor types, supported by demonstrated clinical benefit in earlier clinical trials.
Genelux seeks to bring the promise of oncolytic immunotherapy to patients who need it most.
#BiotechInnovation #Oncology #RedefiningImmunoOncology
Cam Skaugrud retweeted
Why do some tumors fail to respond to immunotherapy? In many cases, it’s a matter of immune recognition.
Tumors classified as immunologically "cold" actively evade the immune system, making them resistant to treatment.
Olvi-Vec is designed to change that equation:
▪ Selectively infecting and lysing tumor cells
▪ Triggering the release of tumor antigens
▪ Driving a systemic immune response
▪ Modifying the tumor microenvironment
The goal: convert cold tumors to hot and make them vulnerable to immune-mediated attack and more responsive to other cancer therapies.
#Immunotherapy #CancerResearch #RedefiningImmunoOncology
Graphics created by NotebookLM. Source: Olvi-Vec proposed mechanisms of action. Yu et al. Gynecologic Oncology Reports. 2026 Aug, Vol. 66, 102145.
Cam Skaugrud retweeted
Featured in @medcitynews News: Our CMO, Dr. Jason Litten, shares his perspective on combination therapies in oncology and the importance of building on existing treatments to improve care for patients.
Drawing on his experience developing therapies for solid tumors, Dr. Litten discusses why many cancers require more than a single therapeutic approach and how combining treatments may help address resistance and improve patient outcomes. He also explores the role immuno-oncology could play alongside established therapies in helping more patients benefit from treatment.
As Genelux continues advancing therapies for solid tumors, conversations around how different treatment modalities can work together remain an important area of research.
Read the full article: bit.ly/4hg4qPO
#Oncology #CancerResearch #ImmunoOncology #CancerCare #ClinicalResearch #Biotechnology #DrugDevelopment
Cam Skaugrud retweeted
Join us at OCRA's International Gynecologic Cancer Conference®, free and online: bit.ly/GynCancerConf26.
This two-day event hosted by @ocrahope is the largest conference for the gynecologic cancer community and offers dedicated programming for ovarian, endometrial, cervical, and rare gynecologic cancers.
Don't miss the Talking Clinical Trials session featuring our Chief Medical Officer, Dr. Jason Litten, and Jane LeBlanc, Director, Clinical Site Liaison, as they discuss the important role clinical trials play in advancing treatment options for people living with ovarian cancer.
#ovariancancer #oncology #RedefiningImmunoOncology
Cam Skaugrud retweeted
September is Ovarian Cancer Awareness Month.
This month, we join the ovarian cancer community in recognizing the patients, families, researchers, nurses, and physicians whose strength, dedication, and perseverance continue to advance progress in the fight against ovarian cancer.
Together, we can raise awareness, support ongoing research, and advocate for those affected by this disease. At Genelux, we are proud to stand alongside the ovarian cancer community and all those working toward better outcomes for patients.
Watch our CEO, Tom Zindrick, share a message in recognition of Ovarian Cancer Awareness Month.
#OvarianCancerAwarenessMonth #OvarianCancer #CancerResearch #Oncology #RedefiningImmunoOncology
Cam Skaugrud retweeted
Progress in ovarian cancer requires continued innovation, especially for patients who continue to face significant treatment challenges.
At Genelux, we're committed to advancing therapies designed to address critical gaps in care and deliver meaningful benefit for patients who need it most.
Swipe to learn more.
#Oncology #Biotech #CancerResearch #RedefiningImmunoOncology
Cam Skaugrud retweeted
Newly published in Frontiers in Oncology, a case report describes a deep and durable response in a platinum-relapsed small cell lung cancer patient following Olvi-Vec-primed immunochemotherapy. The patient achieved 16.7 months of progression-free survival and an 84.6% reduction in target lesion size, exceeding outcomes achieved during prior first-line platinum-based treatment. These findings add to a growing body of evidence supporting the potential of systemic Olvi-Vec to drive anti-tumor activity and enhance responsiveness to platinum-based chemotherapy in difficult-to-treat cancers.
To read the press release and access the published case report: bit.ly/4yqNz3I
Kim and Murphy need to play every day. Jarvis over his head...he will have his time...right now is not it. Move Dubon around....that was the plan going into season prior to Kim/Murph injury. Go with it for a week to ten days. See what happens.
1
1
173
Cam Skaugrud retweeted
Today, we announced our second quarter 2026 financial results and shared key business updates as we continue advancing our late-stage immuno-oncology programs.
As we continue momentum, topline data from our Phase 3 OnPrime/GOG-3076 trial of Olvi-Vec in platinum-resistant/refractory ovarian cancer are expected in 2H26. This registrational study is designed to support a potential regulatory filing.
We also continue to advance our systemic lung cancer programs in both SCLC and NSCLC, with additional dose-finding updates anticipated in 2026 to inform future registrational development.
In addition, recently published translational analyses from our Phase 1b/2 VIRO-15 trial further support Olvi-Vec's tumor-priming mechanism and its potential to promote tumor sensitization to platinum-based chemotherapy.
We look forward to continued execution across our clinical, manufacturing, and operational priorities.
Read the full release here: bit.ly/4g6fsqj
#RedefiningImmunoOncology #OvarianCancer #LungCancer #Biotechnology #ClinicalTrials
I will never know the details of offers/asks and the like. But. As a huge supporter of AA…I am disappointed.
170
Cam Skaugrud retweeted
One of the most important speeches you will hear this year on why we are at war with Iran.
Worth five minutes of your time.
Sen. Tim Sheehy (R-MT) delivers an incredibly powerful speech about Iran.
Watch every second of this.
"Yesterday we saw the president of the United States and many others at Dover Air Force Base presiding over a ceremony that is very sacred to those of us who served, and that is a dignified return of remains from the war zone.
That process happens beginning in the war zone through Dover to the hometown of our fallen heroes. I participated in many of those ceremonies myself to include carrying friends of mine off the plane.
One of those is on this bracelet. He was cut in half by an Iranian EFP.
This regime that we are fighting does not care about our partisan politics. They don't care who you voted for, who you pray to, or where you live. They want to kill all of us. And they don't just say it, they actually do it, and they've been doing it for forty-seven years.
This is a war of choice. The Democrats are correct. It's a war of choice that was begun by a radical lunatic band of terrorists that took over a beautiful nation 47 years ago, took it over with brutality, force, and savagery. And the second they took it over, they didn't free their people, they didn't unleash the largest oil reserves in the world to build schools and bridges.
They took it over to murder their own people and to spread their disgusting ideology across the world, and that is exactly what they have been doing. They don't just say it and talk about it. You don't have to believe what they say. You can simply watch what they've done.
They have attacked families, women, children, innocent people. They don't just attack them and kill them, they rape them. They skin them alive on camera. They celebrate it. They honor those people who do disgusting things that we would put in jail for the rest of their lives in this country, and they do it for fun, and they pay them money to do it, and they're heroes to that nation.
They've done it to friends of mine. They've done it to families who've been in this chamber. And the fact that we sit here and listen to elected officials of this country defend these lunatics who want us all dead. They want all of you dead. They want all of us dead.
They don't want us to disappear with a snap of a finger. They want us to be raped, burned alive, and cut into pieces. Watch the video from October 7. That's what they want to happen from Maine to San Diego, from Seattle to Miami. They want this country turned into a burning husk of its former self, and you don't have to theorize that.
That's what they do. From the 1983 barracks bombing, where 280 Marines were vaporized in a morning, from USS Cole to the Achille Lauro, to every terrorist attack, from the Houthis, Hezbollah, Hamas. These are not humanitarian freedom organizations. They are death-dealing cults, and they want all of us to die brutal deaths.
William Buckley was abducted in 1985, an American military officer. He was skinned alive on camera by the Iranians. American prisoners of war who were captured. They were never called prisoners of war because they were captured by lunatic terrorists, so they were not subject to the Geneva Convention. They were captured and murdered, power drills through their brains. This is in Iraq. These are families that have dealt with this, and they've never gotten a single dime.
These families have never gotten restitution, and not a single president has ever stood up to them. Love Donald Trump or hate him, love his policies, hate ICE, love ICE, whatever. There's never been a single president who has stood up to Iran and hit back. For 47 years, our troops and our families have been absorbing attack after attack after attack all over the world.
And their radical ideology does not stop at the Persian Gulf. It doesn't stop at Tel Aviv. They want to do this everywhere. It's a global radical ideology, and we've been fighting it for half a century.
We didn't start this war. We did not, but we will finish it. And forever wars are not popular with anybody these days. Both sides of the love to attack our forever wars. And I can promise you, being someone overseas wearing the uniform, when you're fighting for your country, you don't care what party's in office, but you're fighting to defend your country, and you turn on the news and see your elected officials stabbing you in the back, telling you that you're failing, that you've failed every goal of the war, is what I just heard.
Last time I checked, we've wiped these bastards out. An occasional missile strike and boats in the straits, that's not military strength. Those are the flailings of a failing empire. Those are the flailings of a nation in collapse because they deserve it. So I encourage our colleagues on both sides of the aisle, whatever's politically convenient, whatever plays well on Twitter or Facebook, think about the people who are deployed right now, standing on that wall with a loaded weapon, who have volunteered to defend our country and our way of life.
Because they are there defending us in a just war, because we did not start a war with the Iranian Revolutionary Guard. They started it with us 47 years ago, and their attacks have gone unanswered for half a century. It's time to fix this problem and make sure another generations of Americans does not have to fight this murderous, savage adversary."
Nick Allen for Dubon straight up. I will never understand that trade from the Astros perspective.
4
178
















